The psychopharmacology of hallucinogens

The paper is a narrative review that draws on historical accounts, epidemiological surveys, experimental human studies, clinical case series, cross-sectional and longitudinal clinical studies, and prior meta-analytic summaries. The authors present a conceptual framework for assessing evidential strength, distinguishing four informal levels of validity: randomized trials (“marble”), reverse-prospective cohort designs (“brick”), case-control studies (“sticks”), and uncontrolled case reports (“mud”). They emphasise that most hallucinogen research has fallen into the lower three categories, with few modern randomized trials. For one focused question—whether psychiatric patients are at greater risk of prolonged psychoses after LSD—the authors performed a quantitative aggregation. Six studies reporting psychotic outcomes after LSD administration were combined into a 2 × 2 contingency table contrasting psychiatric patients with volunteer subjects and psychotic versus non-psychotic reactions; a chi-square test was calculated (x2 = 6.97, p < .01). The extracted text does not report a systematic search strategy, explicit inclusion/exclusion criteria, dates of the literature search, or formal risk-of-bias assessment for included studies. Epidemiological prevalence figures cited derive from national household surveys (NIDA 1990 and a 1993 SAMHSA survey) and from ongoing school-based surveillance.

Epidemiology: National survey data cited by the authors indicate substantial lifetime exposure to hallucinogens in the United States. The 1990 NIDA Household Survey found that 7.6% of people aged 12 and over reported lifetime hallucinogen use and 1.1% reported use in the previous 12 months. A 1993 household survey reported lifetime use of 8.7%. Lifetime use of specific agents was given as 5.5% for LSD and 3% for mescaline. Use was concentrated in young adults (highest in those aged 18–25), more common among men, whites and Hispanics, and associated with urban regions and lower employment/education. Acute effects and physiology: The authors review classic and contemporary human experimental observations. Low LSD doses (possibly 25–50 µg) typically produce intensified perception and transient mood elevation without frank hallucinations; larger doses cause marked perceptual distortion, visual hallucinations, sympathetic arousal (tachycardia, hypertension, mydriasis, piloerection), and duration of effect commonly 6–12 hours. Hallucinatory phenomena are most often visual; delusions are uncommon. Individual responses vary markedly according to set (personality, expectations) and setting (group versus individual administration). Mescaline produced more anxiety and stronger visual effects than MDE in one comparative study, and a randomized double-blind multidose study of DMT in normal volunteers is cited as having developed a multidimensional hallucinogen rating scale. Tolerance and cross-tolerance (e.g. between LSD, psilocybin and mescaline) are described; there are no well-documented withdrawal syndromes for classic hallucinogens. The authors note no documented lethal overdoses from chemically pure LSD in humans, while mentioning reported deaths with MDMA/MDEA and isolated severe exposures. Acute clinical management: In emergency settings the common presentation is an acute adverse reaction or “bad trip.” Clinical distinction between different hallucinogens may be difficult; anticholinergic intoxication or PCP should be considered. The authors report that benzodiazepines (for example oral diazepam 20 mg) have been effective anecdotally for rapid symptom resolution, whereas neuroleptics may sometimes intensify the experience; no controlled trials of treatments for acute intoxication are cited. Psychotic reactions: The literature reports variable attack rates for psychoses following experimentally administered LSD (0.08% to 4.6%), with higher rates among psychiatric inpatients and lower rates among healthy volunteers. The authors’ meta-analysis of six studies found a statistically significant association suggesting that psychiatric patienthood is a risk factor for prolonged psychoses after LSD exposure (chi-square 6.97, p < .01). Clinical descriptions characterise many post-LSD prolonged psychoses as schizoaffective-like, often with prominent visual disturbances, affective symptoms, religiosity/grandiosity, and sometimes better premorbid functioning than non–drug-using schizophrenics. Case series and chart reviews are cited that document earlier illness onset and visual phenomena in drug-associated psychoses; the authors conclude that LSD can act as a psychotogen in certain vulnerable individuals. Hallucinogen persisting perception disorder (HPPD): The review summarises case reports and cross-sectional studies describing persistent or recurrent visual disturbances—geometric pseudohallucinations, peripheral fleeting perceptions, flashes of colour, and positive afterimages—sometimes continuous for months to years. In one study of 123 LSD users, visual disturbances were the primary complaint and were stable in about half the sample over five years. Precipitants included stress, fatigue, dark environments, cannabis or neuroleptic use, and anxiety; HPPD could follow a single LSD dose. Proposed mechanisms include loss or dysfunction of inhibitory interneurons (serotonergic/GABAergic), LSD activity at 5-HT2 receptors and potential involvement of protein kinase C pathways. The authors note a lack of predrug/postdrug experimental designs to test causality. Therapeutic studies: The authors review early therapeutic applications of LSD in psychotherapy and in treating alcoholism. A meta-analysis of 1,603 patients across 42 studies reported “good” or “very good” outcomes in 40% to 62.5% of cases, but the authors emphasise pervasive methodological weaknesses in these studies (lack of randomisation, inadequate controls, non-standardised outcome measures). A large study at Spring Grove compared 150 µg (described as an “active placebo”) with 300–500 µg and found no differences at 12- and 18-month follow-up, though the lower dose may have produced notable psychedelic effects itself. Small randomized trials and uncontrolled designs yield inconsistent or null findings; the authors report that overall there is not compelling evidence favouring LSD over conventional therapies for alcoholism. Human-subjects issues: The review documents ethical concerns around past covert or poorly consented administration (e.g. to children or institutionalised groups) and stresses the need for institutional review, informed consent with quantified discussion of risks/benefits where possible, rigorous outcome measures, placebo controls, random assignment, standardised psychotherapies, blinded raters and follow-up in future research.

The authors interpret the assembled literature as indicating that classical hallucinogens occupy a complex risk–benefit space. Mechanistic understanding (serotonergic receptor pharmacology, animal models, and neuroimaging beginnings) has advanced considerably since initial human experimentation, but clinical utility remains unresolved because early therapeutic studies were methodologically weak and contemporary research has been constrained by regulation. The authors emphasise that hallucinogens can produce acute adverse reactions and, in a subset of vulnerable individuals—particularly those with pre-existing psychiatric illness—may precipitate prolonged psychoses. They also consider HPPD a genuine clinical syndrome in some users, sometimes long-lasting and poorly understood. Key limitations of the evidence base are acknowledged: heterogeneous and often retrospective study designs, small sample sizes, confounding by polypharmacy and adulteration of street drugs, absence of systematic predrug baseline assessments for perceptual disorders, and overall scarcity of modern randomised controlled trials using accepted clinical trial methodology. The authors note that the meta-analytic test performed (six studies combined into a 2 × 2 table) is limited by diversity of sources and methods and should be interpreted cautiously. For research and clinical practice the authors advocate renewed, carefully regulated investigation. They propose integrating human psychopharmacology, animal neuroscience and tissue-culture techniques to identify biological correlates of vulnerability (genetic, excitotoxic, or “kindling”-like mechanisms), and to leverage ligand-specific neuroimaging and molecular genetics. They also recommend that future clinical trials adhere to standard ethical and methodological safeguards (IRB review, informed consent, randomisation, placebo controls, blinded assessment, standardised psychotherapy and follow-up) before therapeutic claims can be substantiated. The overall tone is cautious: hallucinogens remain valuable investigative tools for brain–mind interactions, but their clinical use requires rigorous evidence and ethical oversight.

D. and colleagues conclude that despite progress in understanding the molecular and neuropharmacological actions of hallucinogens since the 1940s, the original question of their clinical usefulness remains unresolved. The authors argue that these agents are scientifically valuable for probing mind–brain relationships and may yield insights into psychoses, affective disorders and hallucinoses if human studies are integrated with animal and cellular research. They call for rigorous, ethically conducted studies—using modern neuroimaging, molecular genetics and standardised clinical trial methods—to identify the basis of individual vulnerability and to determine whether any therapeutic applications can be supported by high-quality evidence.